Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study

To evaluate the effect of the phosphodiesterase 4 inhibitor apremilast in biologic-naïve patients with early peripheral PsA in terms of disease activity, clinical manifestations, patient-perceived outcomes, as well as apremilast’s safety profile in routine care settings of Greece. Non-interventional...

Descripción completa

Detalles Bibliográficos
Autores principales: Sfikakis, Petros P., Vassilopoulos, Dimitrios, Katsifis, Gkikas, Vosvotekas, Georgios, Dimitroulas, Theodoros, Sidiropoulos, Prodromos, Vounotrypidis, Periklis, Bogdanos, Dimitrios P., Georgountzos, Athanasios Ι., Bounas, Andreas G., Georgiou, Panagiotis, Gazi, Souzana, Kataxaki, Evangelia, Liossis, Stamatis-Nick, Theodorou, Evangelos, Papagoras, Charalampos, Theotikos, Evangelos, Vlachoyiannopoulos, Panayiotis, Voulgari, Paraskevi V., Kekki, Angeliki, Antonakopoulos, Nikolaos, Boumpas, Dimitrios T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Observational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073163/
https://www.ncbi.nlm.nih.gov/pubmed/36856816
http://dx.doi.org/10.1007/s00296-022-05269-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073163/
https://www.ncbi.nlm.nih.gov/pubmed/36856816
http://dx.doi.org/10.1007/s00296-022-05269-z

Ejemplares similares